Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Dose, Double-Blind, Double-Dummy, Active Control, Randomized Clinical (Phase II) Study of Two Dosing Regimens of Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Requiring Hospitalisation

Trial Profile

A Multi-Dose, Double-Blind, Double-Dummy, Active Control, Randomized Clinical (Phase II) Study of Two Dosing Regimens of Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Requiring Hospitalisation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Finafloxacin (Primary) ; Finafloxacin (Primary) ; Ciprofloxacin; Ciprofloxacin
  • Indications Bacterial infections; Pyelonephritis; Urinary tract infections
  • Focus Therapeutic Use
  • Sponsors MerLion Pharmaceuticals
  • Most Recent Events

    • 16 Jan 2018 Results of pooled data from two trials (NCT01928433 and NCT00722735) assessing the clinical efficacy and antibacterial activity of finafloxacin compared with ciprofloxacin in the treatment of uUTI and cUTI/PN, were published in the Antimicrobial Agents and Chemotherapy.
    • 16 Jan 2018 Results (n=266) of pooled data from three trial assessing population pharmacokinetics of finafloxacin in healthy volunteers and patients with complicated urinary tract infections, were published in the Antimicrobial Agents and Chemotherapy.
    • 16 Jan 2018 Results (n=225) assessing efficacy of finafloxacin (administered for 5 or 10 days) compared with ciprofloxacin (10 days) in patients with complicated urinary tract infections or acute pyelonephritis requiring hospitalisation, were published in the Antimicrobial Agents and Chemotherapy.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top